CRP and atrial fibrillation: ISIS-CRPRx, a second generation ASO complementary to the coding region of the human c-reactive protein (CRP) mRNA, could reduce the CRP levels substantially but not AF burden in a phase 2 clinical trial in patients with PAF (62).